GLP-1 drugs in early pregnancy: what one study actually tells us

What did @betterlivingforeveryone actually say?

Tiffany, a physician assistant and self-described GLP-1 advocate, reviewed a recent study and told her 101K viewers that GLP-1 exposure around conception was "not linked to any risk of major birth defects." She also said stillbirths, neonatal mortality, and fetal growth restriction were not increased compared to insulin-exposed pregnancies. She was careful to say "this does not mean risk free" and recommended discontinuing GLP-1s before trying to conceive.

She also made a separate claim: that GLP-1s improve fertility, particularly in women with PCOS, by restoring regular menstrual cycles. She framed the whole video around the question of accidental pregnancy on GLP-1 therapy, a genuinely common clinical scenario given the drug class's effect on ovulation in previously anovulatory women.

Overall, the framing was measured. She wasn't cheerleading for GLP-1 use during pregnancy. She was summarizing a systematic review for a lay audience, and she mostly got the tone right.

Does the science back this up?

The study she referenced appears to be a 2024 systematic review and meta-analysis, likely the one published by Cesta et al. or a similar large review examining GLP-1 receptor agonist exposure in early pregnancy. The claim about 36 studies and 2 million patients is consistent with the scale of recent pharmacovigilance meta-analyses in this space.

On the major birth defects question, the evidence is genuinely reassuring but not conclusive. A 2024 meta-analysis published in Diabetes, Obesity and Metabolism found no statistically significant association between GLP-1 receptor agonist exposure in the first trimester and major congenital malformations when compared to insulin or other glucose-lowering drugs. Similarly, a Danish cohort study (Wintzell et al., 2024, NEJM Evidence) found no elevated risk of major birth defects in GLP-1-exposed pregnancies versus unexposed diabetic pregnancies.

The stillbirth and neonatal mortality findings are also consistent with the published literature to date. But here is the honest caveat: most of these studies involve women with type 2 diabetes on liraglutide, not healthy women on semaglutide for weight loss. The populations are different, and the data doesn't transfer cleanly.

What did they get wrong (or right)?

She got the core finding right. The available evidence does not show a signal for major birth defects with periconceptional GLP-1 exposure, and saying we're "not completely in the dark anymore" is a fair characterization of the current evidence base.

The PCOS and fertility claim is also broadly supported. GLP-1 receptor agonists have been shown to improve menstrual regularity in women with PCOS, likely through weight loss and insulin sensitization. Studies including Elkind-Hirsch et al. have documented improved ovulatory function with GLP-1 therapy in this population.

What she underplayed: animal studies with semaglutide have shown embryotoxicity and skeletal abnormalities at doses producing exposures comparable to human therapeutic doses. The FDA label for semaglutide explicitly states it should be discontinued at least two months before planned conception based on these preclinical findings. Wegovy's prescribing information carries a warning about this. She mentioned discontinuing before conception but didn't explain why the two-month window exists, which is a meaningful omission for a clinical audience.

She also didn't distinguish between liraglutide-based human pregnancy data and semaglutide, which has far less human pregnancy data. That conflation matters.

What should you actually know?

If you got pregnant while on a GLP-1, the current human data is more reassuring than alarming, but it comes with real limits. Most data comes from women with type 2 diabetes on older GLP-1 agents, not from the current wave of semaglutide or tirzepatide users taking these drugs for weight management. Those are different drugs, different doses, and different patient populations.

The recommendation to stop GLP-1s at least two months before trying to conceive is not arbitrary. Semaglutide has a long half-life, roughly one week, meaning it stays in your system for weeks after the last dose. The two-month washout is designed to minimize fetal exposure during organogenesis, the window when birth defects are most likely to occur.

If you are using a GLP-1 and your menstrual cycle has become more regular, that is a real effect, not a myth. It also means your contraceptive needs may have changed. This is a clinical conversation worth having with a provider, not a decision to make based on a TikTok, including this one.

The honest bottom line: the data is early, modestly reassuring, and not a green light for continuing GLP-1 therapy through pregnancy.